Evidence map›Paper›PMID 39906569›Full record

ArticleBrain communications2025

MRI versus relapse: optimal activity monitoring for management of progressive multiple sclerosis.

Gavin Giovannoni, Suzannah Hetherington, Eddie Jones, Patricia Dominguez Castro, Himanshu Karu, Soudeh Ansari, Goeril Karlsson, Virginia de Las Heras, Carol Lines

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Gavin GiovannoniThe Faculty of Medicine and Dentistry, Blizard Institute, Queen Mary University of London, London E1 2AT, UK.ORCID https://orcid.org/0000-0001-9995-1700
Suzannah HetheringtonNovartis Pharma AG, Basel CH-4056, Switzerland.
Eddie JonesAdelphi Real World, Manchester SK10 5JB, UK.
Patricia Dominguez CastroNovartis Ireland Ltd, Dublin D04A9N6, Ireland.
Himanshu KaruNovartis Healthcare Pvt. Ltd, Hyderabad 500081, India.
Soudeh AnsariNovartis Pharmaceuticals, Cambridge, MA 02139, USA.
Goeril KarlssonNovartis Pharma AG, Basel CH-4056, Switzerland.
Virginia de Las HerasNovartis Pharma AG, Basel CH-4056, Switzerland.
Carol LinesNovartis Pharma AG, Basel CH-4056, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Secondary progressive multiple sclerosis is often categorized as 'active'/'non-active' based on inflammatory activity on MRI, or relapse; however, the value of MRI/relapse as indicators of disease activity in real-world and clinical trial settings merits further investigation. We separately analysed retrospective data from patients with clinically diagnosed secondary progressive multiple sclerosis in the Adelphi Real-World Disease Specific Programme (a cross-sectional survey) in multiple sclerosis (Adelphi:

Indexed as

active secondary progressive multiple sclerosisinflammatory disease markersMRI activitynon-active secondary progressive multiple sclerosisrelapses

Identifiers

PMID39906569
PMCPMC11791681

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.